DexCom Selected As First Participant For FDA's TEMPO Digital Health Devices Program
The FDA launched the TEMPO pilot to evaluate a new regulatory approach for certain digital health technologies that support chronic disease management while collecting real-world performance data. The initiative is part
DexCom is the first company picked to test a new FDA program that studies how digital health devices work in real life for people managing ongoing health conditions. This shows the FDA trusts DexCom's technology and might make it easier for the company to bring new products to patients faster.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.